Antonio Tito Fojo MD, PhD, americký 9onkolog.
Fojo, Antonio Tito, 1952-....
Fojo, Tito
Fojo, Tito, 1952-
VIAF ID: 80424404 (Personal)
Permalink: http://viaf.org/viaf/80424404
Preferred Forms
- 100 0 _ ‡a Antonio Tito Fojo ‡c MD, PhD, americký 9onkolog.
- 200 _ | ‡a Fojo ‡b Tito
- 100 1 _ ‡a Fojo, Antonio Tito ‡d 1952-
-
-
- 100 1 _ ‡a Fojo, Antonio Tito, ‡d 1952-
- 100 1 _ ‡a Fojo, Antonio Tito, ‡d 1952-....
- 100 1 _ ‡a Fojo, Tito
-
-
4xx's: Alternate Name Forms (8)
Works
Title | Sources |
---|---|
Acetylation of pronase guanidine stable ... 1980 | |
Hematology-oncology therapy | |
MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors | |
Mitosis is not a key target of microtubule agents in patient tumors. | |
Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas. | |
Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate | |
Molecular biology of drug resistance | |
Molecular effects of paclitaxel: myths and reality (a critical review). | |
Moving a pioneer journal into the future. | |
Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr1 gene | |
Multidrug resistance: P-glycoprotein and its allies--the elusive foes. | |
Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs | |
Multiplying therapies and reducing toxicity in metastatic melanoma | |
Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status. | |
Non-inferiority trials: why oncologists must remain wary | |
Novel agents for overcoming recurrent breast cancer | |
A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide | |
Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome | |
Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg With Prolonged Administration in Indolent Neuroendocrine Tumors | |
Oligomerization of p53 precedes its association with dynein and nuclear accumulation | |
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients | |
p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. | |
p53 inhibits hypoxia-inducible factor-stimulated transcription | |
p53 is associated with cellular microtubules and is transported to the nucleus by dynein | |
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. | |
Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death. | |
Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules | |
PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma | |
Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer | |
Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. | |
Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors | |
Phase I trial of a new schedule of romidepsin in patients with advanced cancers | |
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. | |
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer | |
A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma | |
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma | |
Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas | |
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer | |
Practical considerations in the evaluation and management of adrenocortical cancer | |
Precision oncology: a strategy we were not ready to deploy. | |
Precision oncology: origins, optimism, and potential | |
Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs | |
Price, value, and the cost of cancer drugs | |
Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models | |
Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. | |
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. | |
Pseudo-progressing to an unmet need. | |
Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience | |
Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma | |
Radiofrequency ablation for tumor-related massive hematuria | |
RECIST: no longer the sharpest tool in the oncology clinical trials toolbox--reply to point | |
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer | |
Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. | |
Renal cell carcinoma: trying but failing to improve the only curative therapy | |
Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines' | |
Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. | |
Reversal of multidrug resistance: lessons from clinical oncology. | |
Revisiting the role of ABC transporters in multidrug-resistant cancer. | |
Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. | |
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. | |
The role of microtubules in cell biology, neurobiology, and oncology, c2008: | |
Role of radiotherapy in adrenocortical carcinoma | |
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data | |
Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET. | |
SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations | |
A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. | |
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia | |
Sorafenib-induced eruptive melanocytic lesions. | |
Tumour stem cells and drug resistance | |
Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture | |
Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. | |
Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles | |
Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines | |
Why do phase III clinical trials in oncology fail so often? | |
Why RECIST works and why it should stay--counterpoint |